Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
| 1.51 | |
| 1.52 | |
| - | |
| 1.52 | |
| 1.4819 | |
| 1.12-3.62 | |
| 79 372 K | |
| 53 270 K | |
| 0 | |
| -0.21 | |
| 1.639 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Milestone Pharmaceuticals Inc. – Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLO...
- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
